Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.

Ayaka Isogai Kazuki Nozawa Akira NakakamiRie KomakiYuri Ozaki Yuka Endo Ayumi Kataoka Haruru Kotani Akiyo Yoshimura Masaya Hattori Masataka Sawaki Hiroji Iwata

Published in: Breast cancer research and treatment (2024)

Treatments after T-DXd showed a shorter mTTF. Regimens that include trastuzumab may be more effective post-T-DXd treatment than HER2 TKI. Further data are needed to establish the best sequential treatment after T-DXd.

Keyphrases

metastatic breast cancer
radiation therapy
combination therapy
locally advanced